LAB vs TXG
LAB: Standard BioTools provides specialized proteomics and genomics research platforms to accelerate drug discovery, currently undergoing a strategic transition toward a merger with Treeline Biosciences. TXG: 10x Genomics provides advanced single-cell and spatial biology platforms that empower researchers to decode complex biological systems at high resolution.
Side-by-side fundamentals
| Metric | LAB | TXG | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $0.6373 | $71.46 | |
| Market cap | $250M | $9.3B | |
| P/E as of 2026-10-20 | 2.90 | n/a | |
| Net margin FY2025, SEC XBRL | -87.8% | -6.8% | TXG higher |
| Gross margin FY2025, SEC XBRL | +49.9% | +69.1% | TXG higher |
| Operating margin FY2025, SEC XBRL | -129.2% | -9.5% | TXG higher |
| ROE FY2025, SEC XBRL | -17.7% | -5.5% | TXG higher |
| ROA FY2025, SEC XBRL | -13.2% | -4.2% | TXG higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -6.2% | +5.3% | TXG higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | +7.6% | TXG higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.46 | 1.92 | |
| 1-year return as of 2026-10-20 close | -50.2% | +443.8% | TXG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.